Effectiveness of Mavacamten for treating obstructive hypertrophic cardiomyopathy in Canada
Real-World Effectiveness of MAVacamtEN in Canada (MAVEN): A Retrospective Physician Survey of Patient Charts
This study looks at how well mavacamten works for adults in Canada with obstructive hypertrophic cardiomyopathy who are experiencing symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Bristol-Myers Squibb Industry-sponsored |
| Locations | 1 site (London, Ontario) |
| Trial ID | NCT06338202 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the real-world effectiveness of mavacamten in patients diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) in Canada. It involves a retrospective survey of physicians to gather data on patients who have started treatment with mavacamten through the Bristol Myers Squibb CAMZYOS Patient Support Program. The study focuses on adult patients with symptomatic oHCM classified as NYHA class II to III. By analyzing this data, the study seeks to provide insights into the treatment's effectiveness in a real-world setting.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with symptomatic oHCM and have initiated treatment with mavacamten.
Not a fit: Patients who have received any cardiac myosin inhibitor in the six weeks prior to starting mavacamten will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable information on the effectiveness of mavacamten, potentially improving treatment strategies for patients with oHCM.
How similar studies have performed: While this study focuses on real-world effectiveness, similar studies evaluating the effectiveness of mavacamten have shown promising results, indicating a potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who have initiated mavacamten, as part of routine clinical care, through the Bristol Myers Squibb CAMZYOS Patient Support Program for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) * Adult patient (≥18 years of age or as defined per local province/territory) at Index Date (first prescribed dose of mavacamten). * Patient has been diagnosed with symptomatic oHCM of New York Heart Association (NYHA) class II to III at the time of mavacamten initiation. Exclusion Criteria: * In the 6 weeks prior to baseline (i.e., Index Date; date of first prescribed dose of mavacamten), patient has received any cardiac myosin inhibitor (including mavacamten) for oHCM or any other medical condition as part of a clinical trial.
Where this trial is running
London, Ontario
- London Health Science Centre (LHSC) — London, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Email: Clinical.Trials@bms.com
- Phone: 855-907-3286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.